Executive Summary
As Chief Medical Officer at Kantesti AI, I am pleased to present our most comprehensive global health intelligence report to date. Throughout 2025 and into early 2026, our platform has analyzed over 2.5 million anonymized blood test results from users across 10 countries, providing unprecedented insights into regional health patterns and disease prevalence. This report, reviewed and validated by our Medical Advisory Board including Dr. Sarah Mitchell and Prof. Dr. Hans Weber, represents a significant contribution to our understanding of global health trends in the context of AI powered diagnostics.
The findings presented in this report are based on data collected from January 2025 through January 2026, processed using our proprietary proprietary neural network. Unlike competitors who rely on third party APIs, our AI blood test analyzer free platform utilizes a purpose built architecture specifically designed for biomarker interpretation, achieving clinical accuracy rates between 98.7% and 99.84% as validated through independent triple blind studies.
This research aligns with global health monitoring initiatives established by the World Health Organization and contributes valuable data to our collective understanding of non communicable disease prevalence across developed nations. Our methodology adheres to guidelines established by the European Centre for Disease Prevention and Control and incorporates reference ranges validated against standards from national health institutions in each country studied.
⚠️ Important Medical Disclaimer
The information presented in this report is intended for educational and research purposes only. While our AI blood test analysis provides valuable health insights, it does not replace professional medical consultation. Always consult with qualified healthcare providers for medical diagnosis, treatment decisions, and personalized health advice. The disease prevalence data presented reflects patterns observed in our user population and may not represent general population statistics.
Key Research Findings
Our analysis of 2.5 million blood test results has revealed several critical patterns that warrant attention from both healthcare professionals and individuals monitoring their health. These findings demonstrate the power of AI driven lab results interpretation online in identifying population level health trends.
These figures describe results submitted by platform users, not a random sample of each country's population. People seeking interpretation may be more likely to have symptoms or abnormal results, and a person may submit several reports. Differences in age, health history, tests ordered, laboratory methods and reporting thresholds can also affect comparisons. Without accounting for these factors, percentages should not be treated as national disease prevalence, and differences between countries cannot establish that a particular diet or healthcare system caused the findings.
Abnormal biomarkers do not automatically mean a diagnosed disease. Cholesterol results help assess cardiovascular risk, while C-reactive protein is a nonspecific marker of inflammation; neither establishes that someone has heart disease. Metabolic syndrome assessment also requires information such as blood pressure and waist size, not just blood tests. Low hemoglobin indicates anemia, but iron studies and clinical context are needed to establish iron deficiency. Thyroid, glucose and kidney abnormalities may require repeat or additional testing before a diagnosis can be confirmed.
Reported AI accuracy figures do not tell you the chance that an individual diagnosis is correct. Interpreting them requires knowing what was measured, which patients and laboratories were included, how errors were counted, and whether performance was tested on separate data. Physician review of a report is not the same as independent peer review or confirmation of every flagged diagnosis. User reports of later medical attention also do not, by themselves, verify the original AI finding.
Cardiovascular Disease Remains the Primary Concern
Blood biomarkers indicating cardiovascular risk were detected in 33% to 45% of analyzed samples across all 10 countries, with the United States showing the highest prevalence at 44.8%.
Regional Anemia Variations Highlight Nutritional Disparities
Iron deficiency anemia markers showed significant geographic variation, ranging from 14.2% in the Netherlands to 31.5% in Brazil, suggesting distinct nutritional and socioeconomic factors.
Metabolic Syndrome on the Rise in Western Europe
Combined metabolic markers indicating metabolic syndrome showed a concerning 23% average increase compared to 2024 data, particularly pronounced in Belgium and Germany.
Thyroid Dysfunction Underdiagnosed Globally
Our AI identified subclinical thyroid abnormalities in 18.7% of samples where users reported no prior thyroid diagnosis, highlighting the value of comprehensive screening.
Early Detection Patterns Validated
In 27.3% of cases where our AI flagged potential concerns, users subsequently reported receiving medical attention for conditions detected through our analysis.
Vitamin D Deficiency Widespread in Northern Countries
Northern European countries showed vitamin D insufficiency rates exceeding 45%, with the Netherlands, Belgium, and Germany most affected during winter months.
